Sun-627

Phase 2

SSundance Biosciences, Inc.

Sun-627 is one of 5 therapeutic programs targeting Primary Progressive Multiple Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Primary Progressive Multiple SclerosisRecruiting

Primary Progressive Multiple SclerosisPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Primary Progressive Multiple Sclerosis

#DrugCompanyPhaseTrials

Gilenya

Ocrevus

6 3

Glucophage

EMD Serono

Approved

—4

Sun-627

SSundance Biosciences, Inc.

Phase 2

1 5

Orca-Q

SStanford University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Primary Progressive Multiple Sclerosis

NCT07840326

Clinical

Trials by Indication[1]

Primary Progressive Multiple Sclerosis1 trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

Recruiting·SSundance Biosciences, Inc.·Phase 2·NCT07840326·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sun-627. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sun-627. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sundance Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSundance Biosciences, Inc.

Sun-627

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Primary Progressive Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News